We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
Last close (EUR)229.56+6.91 (+3.10%)as of 4 Nov 2026
Funds that hold it1One fund per scheme
Held through a master fund10 buy the stock themselves
Largest weight in a single fund3.59%Of that fund's NAV
Median weight3.59%Half the funds hold more than this
What does ASND do
Ascendis Pharma A/S
Danish biotech company that develops drugs using its TransCon controlled-release technology, focused on childhood endocrine disorders and cancer. Most revenue comes from sales of its approved drugs
SkytrofaTransCon (drug platform)Endocrine drugs
Which funds let you invest in ASND
Sorted by weight held, largest first
Investors in Thailand can buy ASND through 1 mutual funds open to retail investors. Most of them (1 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds ASND.
Showing 1 of 1 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance
ASND share price
0.00%
Price change over the selected periodN/A
50-day average
200-day average
Thai funds holding ASND
1 funds · Highest 3.59% · Median 3.59%
How the weights are spread
Number of funds by weight range
0
0
1
0
0
0
< 1%1–3%3–5%5–8%8–12%12%+
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
How many funds each AMC holds it through
TISCOASSET
How Thai money reaches ASND
1 master funds
Master fund
Thai funds using this route
Master fund's ASND weight
Polar Capital Funds plc - Biotechnology
1
3.59%
Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Financial statements: SEC EDGAR · Ratios: Market data · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.
Valuation and key ratios
Ascendis Pharma A/S · NASDAQ · ราคาแปลงจาก ASND (USD) · Fiscal year ends in January
Market cap14.2B EUR0.06 billion shares
P/EN/AFY2025 EPS is negative
Forward P/E21.2xBased on forecast 12-month earnings
P/S13.6x
EV/EBITDA75.3x
Dividend yield0.00%0.00 EUR per share a year
ROE169.8%Net profit ÷ shareholders' equity
Debt to equity (D/E)−5.00xInterest-bearing debt
Beta0.38Against the S&P 500
Gross margin86.8%FY2025
Operating margin−18.9%FY2025
Net margin−31.7%FY2025
Price ratios use the latest close shown on this page · Forward P/E, P/S and EV/EBITDA from Market data · Beta from 5 years of monthly returns · Total dividends over the last 12 months
Company health made simple
From the FY2025 statements
Sales growth208.0%Fast growth
Yearly average over the last 4 years · Latest annual sales 720.0M EUR
Profit from sales−32%Thin margin
For every 100 EUR of sales, about −32 EUR is left as net profit
Dividend0.00%No dividend
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
1-year share price+23.9%Up
Now 6.9% below its 1-year high
A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds
Financial statements
Revenue grows 208.0% a year on average · EPS grows N/A a year on average
Annual · last 5 fiscal years
Revenue and net profit
FY20218.0M EUR−384.0M EUR
FY202251.0M EUR−583.0M EUR
FY2023267.0M EUR−481.0M EUR
FY2024364.0M EUR−378.0M EUR
FY2025720.0M EUR−228.0M EUR
Total revenue
Net profit
Quarterly · last 5 quarters
Revenue and net profit
Q2 FY2025158.0M EUR−38.9M EUR
Q3 FY2025213.6M EUR−61.0M EUR
Q4 FY2025247.5M EUR−33.6M EUR
Q1 FY2026246.6M EUR629.3M EUR
Q2 FY2026339.3M EUR207.0M EUR
Annual income statement, balance sheet and cash flow
Item (EUR)
FY2021
FY2022
FY2023
FY2024
FY2025
Total revenue
8.0M EUR
51.0M EUR
267.0M EUR
364.0M EUR
720.0M EUR
Gross profit
4.0M EUR
39.0M EUR
222.0M EUR
319.0M EUR
625.0M EUR
Operating profit
Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR
Technical analysis
Closed at 229.56 EUR on 4 Nov 2026
Daily trendClear uptrendScore 1.00 on a scale of −1 to +1 · 1254 bars
RSI(14)
68.9
ADX(14)
34.4
Position in the price range
73%
Weekly trendClear uptrendScore 1.00 on a scale of −1 to +1 · 262 bars
RSI(14)
56.4
ADX(14)
17.1
Position in the price range
76%
Monthly trendClear uptrendScore 1.00 on a scale of −1 to +1 · 61 bars
RSI(14)
64.4
ADX(14)
47.8
Position in the price range
90%
Moving averages (daily)
Period
SMA
EMA
Price vs line
10 days
221.46
220.87
Above
20 days
212.37
216.44
Above
50 days
215.63
215.35
Above
100 days
220.68
215.29
Above
200 days
Indicators (daily)
Indicator
Value
Signal
RSI(14)
68.87
Up
MACD(12,26)
4.20
Up
ADX(14)
34.43
Neutral
ATR(14) % of price
1.26
Neutral
Support and resistance (weekly pivots)
s3210
s2213
s1
Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice
One fund counted per scheme · Funds investing through a master fund show the master fund's weight in ASND, not the look-through weight · Past performance is not a guarantee of future performance
TBIOTECHTISCO Biotechnology Healthcare Fund